Today, on 29 November, the financial statements of the JSC Grindeks on the first nine months of 2013, submitted to “Nasdaq OMX Riga”, indicate that the Group’s turnover in the first nine months 2013 was 56.5 million lats, which is by 6.4 million lats or 12.8% more than in the first nine months of 2012. Whereas, the net profit of the Group, related to the shareholders of the holding company, in the first nine months of 2013 was 5.4 million lats that comparing of the first nine months of 2012 has increased by 0.4 million lats or 8%. The gross profit margin in the first nine months of 2013 was 59.5%, whereas, the net profit margin was 9.6%. In the first nine months of 2013 the products manufactured by the Group were exported to 55 countries all over the world for the total amount of 53.6 million lats that comparing to the first nine months of 2012 has increased by 6.2 million lats or 13.1%.
The sales volume of the final dosage forms of Grindeks in the first nine months of 2013 was 50.1 million lats and has increased comparing to the same period of the previous year by 3.4 million lats or 7.3%. The main markets of the final dosage form are Russia, other CIS countries, Georgia and the Baltic States. The sales amount in Russia, other CIS countries and Georgia in the first nine months of 2013 was 43 million lats, which is by 2.6 million lats or 6.4% more than in the first nine months of 2012. Whereas, the sales amount of final dosage forms in the Baltic States and other European countries reached 7 million lats, which is by 0.7 million lats or 11.1% more than in the first nine months of 2012.
The sales of active pharmaceutical ingredients in the first nine months of 2013 reached 6.4 million lats, which is by 3 million lats or 88.2% more than in the first nine months of 2012. The main export markets of the Grindeks active pharmaceutical ingredients are the Netherlands, Germany, Canada, Ireland and Japan. The most demanded active pharmaceutical ingredients of Grindeks are zopiclone, oxytocin, ftorafur (tegafur) and UDCA (ursodeoxycholic acid).
JSC Grindeks Chairman of the Board Juris Bundulis: “In the first nine months of 2013 the turnover and profit growth is significant, but less than originally planned. Grindeks has always been the long-term development-oriented company, and therefore we will continue to invest in both product portfolio development and acquisition of new markets. We will continue activities in China and the Scandinavian countries, as well as we will realize a number of important niche projects in several Western Europe countries. We will pay even more attention on generics portfolio development, research and development of original products, effective cost management and improvement of performance of 13 representative offices”.